Science & Pipeline

Approach, Programs, and Progress
A purple and cyan fibril graphicA purple and cyan fibril graphic

Attralus PipelinE

Diagnosing & reversing the underlying pathology in the most debilitating systemic amyloid diseases

ATTR AL Other (e.g. ALECT2)

Our Novel Pan-Amyloid Targeting Pipeline

Potential to diagnose & reverse the underlying pathology of up to 30 systemic amyloid diseases

Program

Underlying Technology

Stage

Pre-clinical
Phase 1
Phase 2
Phase 3

AT-01

Diagnostic
& Monitoring
EARLY
PHASE 2
Polybasic peptide radiotracer
An icon representing that this technology is owned by Attralus
More Info
More Info

AT-02

Innovative Therapeutic
LATE
PRE-CLINICAL
Novel peptide-immunoglobulin fusion
An icon representing that this technology is owned by Attralus
More Info
More Info

AT-03

Innovative Therapeutic
LATE
PRE-CLINICAL
Novel Fc-fusion protein
An icon representing that this technology is owned by Attralus
More Info
More Info
P5+14 peptide
Base Platform Technology
More Info
An icon representing that this technology is owned by Attralus
Denotes that Attralus has commercial rights
Attralus has commercial rights to all 3 program technologies

AT-03

Novel Fc-fusion protein

Attralus is developing a novel Fc fusion protein that binds to amyloid utilizing a natural accessory component common to all amyloid fibrils. AT-03 utilizes a native protein armed with an Fc to stimulate the immune system creating the potential to clear amyloid.

close button😔

AT-02

Novel peptide-immunoglobulin fusion

Attralus is developing a novel peptide-immunoglobulin fusion in which an amyloid-reactive peptide (similar to AT-01) is fused to an Ig light chain (LC), which when associated with an Ig heavy chain (HC), yields a multi amyloid-reactive opsonin that can tightly bind and remove multiple forms of amyloid and stimulate immune activation of natural clearance mechanisms.  

AT-02 has unique binding properties that enable a significantly higher avidity and accessibility to amyloid than typical antibodies. It does this by utilizing multiple binding sites (including fibrils and amyloid bound proteoglycans) that utilizes both charge and structure. AT-02 remains highly specific while enhancing phagocytosis of amyloid by macrophages.  

close button😔

AT-01

Polybasic peptide radiotracer

Follow our AT-01 Clinical Trial at ClinicalTrials.gov

Attralus has developed a synthetic, novel, peptide radiotracer – AT-01 (¹²⁴I-p5+14) - that binds to many forms of amyloid, including AL, ATTR, and ALECT2. It is composed of an iodine-124 labeled peptide p5+14 and may be utilized for diagnostics, patient selection, staging, and disease/treatment monitoring purposes. PET/CT imaging using this radio tracer may provide a rapid, first-line diagnostic reagent for quantitative monitoring of response to therapy in patients with diverse forms of systemic amyloidosis.

The first-in-man, Phase 1/2, study of AT-01 for PET/CT imaging of 88 patients with systemic amyloidosis is currently underway (NCT03678259). Initial image data show AT-01 is capable of detecting:

  • AL amyloid in the heart, kidney, liver, spleen, lung, adrenal gland, and pancreas
  • TTR amyloid in the heart, nerves, lung, and connective tissue in hands and spine
  • ALECT2 amyloid in the kidneys, liver, spleen, and adrenal gland
  • Pre-Symptomatic cardiac disease in AL and ATTR
close button😔

Scientific Approach

Proprietary pan-amyloid targeting agents to transform diagnosis & treatment

A New Path Forward

Our technology leverages proprietary pan-amyloid targeting agents with the potential to diagnose and treat all forms and stages of systemic amyloidosis. Attralus is focused on targeting the underlying pathology in all systemic amyloid diseases, with the goal of developing potential treatments for many subtypes of amyloidosis.

The Science

In contrast to current treatments, which reduce the formation of new amyloid fibrils and slow disease progression but do not address already deposited amyloid, Attralus is developing novel pan-amyloid targeting agents to directly bind and remove toxic amyloid fibrils from organs and tissues throughout the body, with the potential to reverse disease pathology. Unlike current monoclonal antibodies in development for systemic amyloidosis, Attralus’s therapeutics target motifs that are universally and ubiquitously presented on all amyloid fibrils. This pan-amyloid binding profile allows Attralus’s therapeutics to target multiple types of amyloid fibrils including AL, ATTR, ALECT2 and others.

Phase 1 data for our imaging agent, AT-01, show excellent binding and imaging properties for the three most common systemic amyloid diseases —ATTR (transthyretin), AL (light chain), and ALECT2 amyloidosis—as well as other rarer forms.

Selected images of systemic amyloidosis patients imaged with AT-01
Examples of Images for Ph 1/2 trial of AT-01 in ATTR, AL and ALECT2 patients

Get in Touch

Partnership, Careers, Press, OR PATIENT Inquiries

Thank you

Your message has been received!

We will reply as soon as possible.
Oops! Something went wrong while submitting the form.
A purple and cyan fibril graphic

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.
close button😔

Attralus Job

AD/Director, Program Management
Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics...
Read More

AD/Director, Program Management

<< Back

Overview

Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics. We are developing pan-amyloid targeting agents that facilitate diagnosis, and the development of novel immunotherapies designed to clear amyloid fibrils in patients with systemic amyloid diseases. We aim to improve the diagnosis and treatment of systemic amyloid diseases, such as light chain (AL), transthyretin (ATTR), and LECT2 amyloidosis, to increase patient survival and quality of life.

Attralus’ technology has broad applications and the potential to address up to 30 systemic amyloid based diseases.  Attralus has a diagnostic imaging agent currently in a ph 1/2 trial, positioned to potentially be the first approved diagnostic specifically for amyloidosis. The company also has 2 novel therapeutic fusion proteins, directed at amyloid removal, that are in pre-clinical development

Headquartered in South San Francisco and founded in 2019, Attralus has recently completed a Series A funding with VenBio to carry forward its mission to improve the lives of systemic amyloidosis patients

Description

The AD/Director, Program Management will be responsible for providing both strategic and hands-on program and project management expertise. Initially reporting directly to the CEO, the AD/Director will be responsible for creating the program plan and budget and providing daily coordination and tracking of critical activities, assuring all milestones and deliverables are met. The Director will be responsible for developing the program management processes and procedures for the company, determining appropriate software and other tools, structuring regular meetings and communication within the company and with external collaborators.

Responsibilities

Collaborate with the management team to provide project management leadership and execution activities within the company and between external partners and Attralus teams.

Develop and execute integrated cross-functional project plans with established goals, milestones, timelines and budget, with a key focus on bringing pre-clinical therapeutic programs into early clinical development

Conduct and direct day-to-day program activities to meet milestones; monitoring critical path activities to ensure delivery of program objectives.

Drive planning for key drug development milestones.

Maintain effective communication with the management team through oral and written correspondence and ensure adequate documentation of each communication. 

Always use/model/maintain/promote best practices in Program Management, including the use of agendas, minutes, dashboards, maintain document repository, establish and implement templates, tools, and processes to drive efficiency, alignment, communication, and effective planning.

Create and maintain easily accessible, high level program documents in electronic format. 

Recommend, manage and train on necessary software and tools.

Identify, develop and/or maintain an appropriate electronic platform (SharePoint, Shared Folders, etc.) for reporting/archiving/documentation of relevant program information, records, etc. 

Conduct risk management, contingency and scenario planning using appropriate program management tools.

Identify program issues or resource gaps and facilitate resolution.

Communicate program information and support development of program presentations to senior leadership, board members, investors and other key stakeholders as appropriate.

Contribute to budgetary planning at the program level.

Facilitate adherence to Aurora’s governance processes; work with key stakeholders to prepare for those interactions; lead/support as appropriate. Ensure implementation of governance decisions.

Qualifications

Minimum of a BA/BS in a scientific disciplined is required, Advance degree preferred

7+ years of program management or equivalent experience in a pharmaceutical or biotechnology organization.

Experience with research/pre-clinical and early clinical development project planning required. PM Certification is a plus.

Rare disease experience a strong plus (not required).

Desire and ability to work in a start-up, fast paced organization where you will wear many hats.

Must have excellent verbal and written communication skills as well as exceptional organizational capability.

Ability to drive program plans and timelines (across multiple functional areas) is essential.  Proven success in goal setting, prioritization and time management is required.

Understanding of FDA and/or EMA quality and regulatory processes. Prior experience with regulatory filings is desirable. 

Experience working with external partners is desirable.

Ability to work independently in decision-making and resolution of program obstacles and conflicts.

Familiarity with developing budgets and forecasting is desirable.

Ability to function autonomously, with an appreciation of detail while being cognizant of “the big picture.”

Have a patient-first mindset. All decisions made with patients in mind.

Proficiency with Microsoft Word, Excel, PowerPoint, and Project is required.

Benefits/Equal Opportunity Employer

Attralus, Inc. offers both comprehensive benefits and Paid Time Off (PTO) plans for employees, which begin on the first day of employment.

Attralus, Inc. is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.